<DOC>
	<DOCNO>NCT00005040</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Relapsed Refractory Non- Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete partial response rate , duration complete response , freedom progression , event free survival , overall survival patient relapse refractory intermediate high grade lymphoma treat arsenic trioxide . II . Determine toxicity regimen patient . OUTLINE : Patients receive arsenic trioxide IV 2-4 hour maximum 25 cumulative day follow rest period 3-4 week . Patients complete partial response may receive 6 additional course absence disease progression unacceptable toxicity . Patients minor response ( 25-50 % tumor regression ) may also receive course treatment . Patients follow 4 week . PROJECTED ACCRUAL : A total 22-41 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove nonHodgkin 's lymphoma ( NHL ) relapse follow resistant least 1 standard anticancer therapy curative therapy exist Intermediate high grade NHL one follow type : Transformed low grade Diffuse small cleave cell Diffuse large cell ( include diffuse mixed cell immunoblastic large cell ) Primary mediastinal Bcell Follicular large cell ( follicular center cell grade III follicular cell ) Anaplastic large cell Angiocentric ( include nasal Tcell pulmonary Bcell ) Angioimmunoblastic Tcell lymphoma Peripheral Tcell Intestinal Tcell Intravascular lymphomatosis Lymphoblastic Diffuse small noncleaved cell/Burkitt 's Adult Tcell leukemia/lymphoma Mantle cell Measurable disease A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 17 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 4 month study No active serious infection control antibiotic No grade 3 bad preexist neurological abnormality , regardless causality HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 2 prior chemotherapy regimen ( e.g. , one frontline plus one salvage regimen ) At least 2 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : At least 1 month since prior radiotherapy recover Surgery : Not specify Other : See Disease Characteristics At least 2 week since prior investigational agent recover No concurrent intrathecal drug</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>